NICEVIVA
MONOGRAPH SPEC LATEST 2026

Cornus officinalis

TRADITIONAL ASIAN · Evidence Monograph

Cornus officinalis is an evidence-graded traditional asian monograph evaluated across 37 peer-reviewed PubMed studies (0 meta-analyses, 0 systematic reviews, and 1 randomized controlled trials, encompassing n = 151 cumulative participants). Current clinical evidence is rated GRADE Low (2.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) Low (2.0 / 4.0)
Indexed PubMed Studies 37 Studies
Meta-Analyses · Reviews 0 Meta · 0 Systematic Reviews
Randomized Trials (RCT) 1 RCTs (1 Double-Blind)
Cumulative Participants n = 151
Reported Trial Dosages 400 mg · 17.8 mg · 9.8 mg
Trial Duration Range 12 weeks · 28 days · 55 days
Reading Time ~19 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 37 indexed PubMed studies, GRADE Low).
  2. 02 Adults matching clinical trial dosing protocols (400 mg · 17.8 mg · 9.8 mg) over a structured 12 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
With Breakfast or Lunch
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary traditional asian clinical efficacy (37 PubMed studies)
Quantitative biomarker & outcome analysis (3 studies with effect-size/sample data)
Randomized controlled trial verification (1 RCTs · 1 double-blind)
Systematic review & meta-analysis synthesis (0 meta-analyses · 0 reviews)
01

What Is Cornus officinalis & Why Does Form Matter?

Cornus officinalis is classified under TRADITIONAL ASIAN and has been investigated across 37 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (400 mg, 17.8 mg, 9.8 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Cornus officinalis frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (1 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Cornus officinalis acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Cornus officinalis an overall evidence rating of GRADE Low (2.0 / 4.0) based on 37 PubMed studies: 0 meta-analyses, 0 systematic reviews, and 1 randomized controlled trials (1 double-blind, n = 151 total participants).

Representative peer-reviewed findings include: • PMID:41761792 (2026) — "Synergistic immunomodulatory effects of Cistanche deserticola, Schisandra chinensis and Cornus officinalis on elderly patients with recurrent pneumonia: A retrospective clinical controlled trial." (CONCLUSION: This method has a good immunomodulatory effect on elderly patients with recurrent pneumonia and is worthy of further promotion and application.) • PMID:26972502 (2016) — "Synergistic interaction of effective parts in Rehmanniae Radix and Cornus officinalis ameliorates renal injury in C57BL/KsJ-db/db diabetic mice: Involvement of suppression of AGEs/RAGE/SphK1 signaling pathway." (CONCLUSIONS: These findings suggest that the inhibitory effect of CBP, IGCO, TACO and IGRR on the activation of AGEs/RAGE/SphK1 signaling pathway in db/db diabetic mice kidney is a novel mechanism by which CBP, IGCO, TACO and IGRR exerts renoprotective effects on DN.) • PMID:33187261 (2020) — "Efficacy and Safety of Combined Extracts of Cornus officinalis and Ribes fasciculatum for Body Fat Reduction in Overweight Women." (These results suggest that treatment of COEC extract reduces body fat percentage and mass in Korean overweight women, indicating it as a protective functional agent for obesity.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 400 mg · 17.8 mg · 9.8 mg · 1.4 mg over 12 weeks · 28 days · 55 days · 30 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Cornus officinalis, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (400 mg · 17.8 mg · 9.8 mg) and re-evaluate efficacy after 12 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (37 Studies) · 3 Quantitative Analyses

01
RANDOMIZED TRIAL (RCT) Pakistan journal of pharmaceutical sciences (2026) PMID: 41761792 ↗
Synergistic immunomodulatory effects of Cistanche deserticola, Schisandra chinensis and Cornus officinalis on elderly patients with recurrent pneumonia: A retrospective clinical controlled trial.
Clinical Trial Synthesis 2026 Randomized Controlled Trial (RCT) published in Pakistan journal of pharmaceutical sciences involving n = 75 participants; statistical significance reported at p = 0.05. Key conclusion: CONCLUSION: This method has a good immunomodulatory effect on elderly patients with recurrent pneumonia and is worthy of further promotion and application.
View Original PubMed Abstract ↓

BACKGROUND: Recurrent pneumonia in the elderly can repeatedly damage lung function and reduce quality of life, posing certain challenges to clinical treatment. OBJECTIVE: To analyze the synergistic immune regulatory effects of Cistanche deserticola, Schisandra chinensis and Cornus officinalis on elderly patients with recurrent pneumonia. METHODS: A total of 165 patients with recurrent pneumonia from Chengde Medical University from January 2024 to January 2025 were recruited, 158 were enrolled after exclusions, 8 lost to follow-up, and 150 finally analyzed. The 150 patients were divided into MC group (n=75) and MA group (n=75). Both groups were treated with Ma Xing Shi Gan Tang and Azithromycin, while the MC group was additionally treated with Cistanche deserticola, Schisandra chinensis and Cornus officinalis. The main evaluation includes the Traditional Chinese Medicine Syndrome Score (TCMSS), lung function indicators, inflammation indicators, immune indicator levels and clinical efficacy of two groups. Secondary outcomes include quality of life scores, incidence of complications and adverse reactions. RESULTS: After treatment, the lung function indicators, immune indicators and clinical efficacy in MC group were higher than in the CC group; the TCMSS and inflammatory indicators were lower in the CC group (P>0.05). No significant difference in quality of life score, incidence of complications and adverse reactions between the two groups (P<0.05). CONCLUSION: This method has a good immunomodulatory effect on elderly patients with recurrent pneumonia and is worthy of further promotion and application.

02
CLINICAL STUDY Journal of ethnopharmacology (2016) PMID: 26972502 ↗
Synergistic interaction of effective parts in Rehmanniae Radix and Cornus officinalis ameliorates renal injury in C57BL/KsJ-db/db diabetic mice: Involvement of suppression of AGEs/RAGE/SphK1 signaling pathway.
Clinical Trial Synthesis 2016 Clinical Study published in Journal of ethnopharmacology. Key conclusion: CONCLUSIONS: These findings suggest that the inhibitory effect of CBP, IGCO, TACO and IGRR on the activation of AGEs/RAGE/SphK1 signaling pathway in db/db diabetic mice kidney is a novel mechanism by which CBP, IGCO, TACO and IGRR exerts renoprotective effects on DN.
View Original PubMed Abstract ↓

ETHNOPHARMACOLOGICAL RELEVANCE: Rehmanniae Radix (RR) and Cornus officinalis (CO) are two traditional Chinese medicines widely used in China for treating diabetes mellitus and its complications, such as diabetic nephropathy. Iridoid glycoside of Cornus officinalis (IGCO), triterpenoid acid of Cornus officinalis (TACO) and iridoid glycoside of Rehmanniae Radix (IGRR) formed an innovative formula named combinatorial bioactive parts (CBP). The aims of the present study were to investigate the renoprotective effects of CBP on DN through the inhibition of AGEs/RAGE/SphK1 signaling pathway activation, and identify the advantage of CBP compared with IGCO, TACO, IGRR. MATERIALS AND METHODS: The db/db diabetic renal injury model was used to examine the renoprotective effects of CBP, IGCO, TACO and IGRR. For mechanistic studies, diabetic symptoms, renal functions, and pathohistology of pancreas and kidney were evaluated. AGEs/RAGE/SphK1 pathway were determined. RESULTS: CBP, IGCO, TACO and IGRR inhibited the decrease in serum insulin levels and the increases in urine volume, food consumption, water intake, TC, TG, glycated serum protein, fasting blood glucose levels, 24h urine protein levels, and serum levels of urea nitrogen and creatinine. It also prevented ECM accumulation and improved the histology of pancreas and kidney, and alleviated the structural alterations in mesangial cells and podocytes in renal cortex. Moreover, CBP, IGCO, TACO and IGRR down-regulated the elevated staining, protein levels of RAGE, SphK1, TGF-β and NF-κB. Among the treatment groups, CBP produced the strongest effects. CONCLUSIONS: These findings suggest that the inhibitory effect of CBP, IGCO, TACO and IGRR on the activation of AGEs/RAGE/SphK1 signaling pathway in db/db diabetic mice kidney is a novel mechanism by which CBP, IGCO, TACO and IGRR exerts renoprotective effects on DN. Among all the groups, CBP produced the strongest effect while IGCO, TACO and IGRR produced weaker effects.

03
CLINICAL STUDY Journal of clinical medicine (2020) PMID: 33187261 ↗
Efficacy and Safety of Combined Extracts of Cornus officinalis and Ribes fasciculatum for Body Fat Reduction in Overweight Women.
Clinical Trial Synthesis 2020 Randomized Controlled Trial (RCT) published in Journal of clinical medicine involving n = 76 participants; statistical significance reported at p = 0.022. Key conclusion: These results suggest that treatment of COEC extract reduces body fat percentage and mass in Korean overweight women, indicating it as a protective functional agent for obesity.
View Original PubMed Abstract ↓

Obesity is a medical condition that presents excessive fat accumulation with high risk of serious chronic diseases. The aim of this clinical trial is to investigate the anti-obesity effects of Cornus officinalis (CO) and Ribes fasciculatum (RF) on body fat reduction in Korean overweight women. A total of 147 overweight female participants enrolled in double-blinded clinical trial for 12 weeks and 76 participants completed the clinical study. Participants were treated with four CO and RF mixture (COEC; 400 mg per tablet) or four placebo tablets once a day. Obesity associated parameters (body weight, body mass index (BMI), waist circumference, waist-to-hip ratio, body fat percentage and body fat mass) and safety assessment were analyzed. After 12 weeks of COEC treatment, primary outcomes such as body fat percentage (0.76% vs. 0.01%; p = 0.022) and mass (1.1 kg vs. 0.5 kg; p = 0.049) were significantly decreased. In addition, the results were statistically significant between the COEC and placebo groups, strongly indicated that COEC had anti-obesity effects on overweight women. Secondary outcomes-including body weight, waist and hip circumference, waist-to-hip ratio, body mass index and computed tomography measurement of visceral fat area, subcutaneous fat area, total abdominal fat area and visceral-to-subcutaneous fat ratio-were reduced in COEC-treated group, but no statistical differences were found between the COEC and placebo groups. The safety assessment did not differ between the two groups. These results suggest that treatment of COEC extract reduces body fat percentage and mass in Korean overweight women, indicating it as a protective functional agent for obesity.

04
CLINICAL STUDY Journal of cellular and molecular medicine (2026) PMID: 41896449 ↗
Wine-Processed Cornus officinalis Ameliorates Osteoarthritis via Modulating M1/M2 Macrophage Polarization.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of cellular and molecular medicine. Key conclusion: pCO improved joint function and attenuated cartilage degeneration and synovial lesions, which were associated with the promotion of articular cartilage protection via the modulation of M1/M2 macrophage polarization.
View Original PubMed Abstract ↓

Cornus officinalis (CO) is a traditional herbal medicine renowned in Traditional Chinese Medicine (TCM) for its properties of tonifying the liver and kidney and replenishing vital essence. Meanwhile, wine-processed CO (pCO) exhibits superior pharmacological effects, including anti-inflammatory, antioxidant and anti-fibrotic activities. However, the immunomodulatory mechanism of pCO in osteoarthritis (OA) remains unclear. OA models were established in Sprague-Dawley rats via anterior cruciate ligament transection (ACLT). Network pharmacology and molecular docking were used to predict potential targets of pCO against OA, which were validated through behavioural tests, histomorphological staining and immunohistochemistry. HPLC-Q-Orbitrap-MS analysis identified key differential compounds between raw and wine-processed CO. The immunomodulatory effects of pCO were further confirmed by ELISA, immunofluorescence staining and RT-qPCR. pCO ameliorated joint pain and cartilage damage in OA rats by reducing pro-inflammatory factors (IL-1β, COX-2, IL-12) and promoting anti-inflammatory factors (IL-10, TGF-β1) in serum and synovial fluid. Network pharmacology combined with in vivo experiments revealed that pCO attenuated chondrocyte degeneration and apoptosis. Mechanistically, pCO modulated macrophage polarization by suppressing the M1 phenotype (CD86, iNOS) while promoting the M2 phenotype (CD206, TGF-β1, Arg-1), which revealed the key mechanism underlying its therapeutic effects against OA. pCO improved joint function and attenuated cartilage degeneration and synovial lesions, which were associated with the promotion of articular cartilage protection via the modulation of M1/M2 macrophage polarization. © 2026 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

05
CLINICAL STUDY Fitoterapia (2026) PMID: 41850592 ↗
Cornus officinalis Siebold & Zucc. ethanol extract alleviates primary dysmenorrhea via anti-inflammatory and spasmolytic effects: network pharmacology and experimental verification.
Clinical Trial Synthesis 2026 Clinical Study published in Fitoterapia. Key conclusion: In ex vivo experiments, COEE inhibited spontaneous and agonist-induced uterine contractions, attenuated CaCl2-induced contractile recovery, and reduced Bay K 8644 evoked Ca2+-mediated contractions.
View Original PubMed Abstract ↓

This study investigated the effects and mechanisms of Cornus officinalis Siebold & Zucc. ethanol extract (COEE) on primary dysmenorrhea (PD). COEE administration dose-dependently reduced writhing times, prolonged writhing latency, decreased uterine prostaglandin F2α (PGF2α) levels and pro-inflammatory mediators, and improved histopathological signs of uterine inflammation. Furthermore, COEE suppressed the activation of the TLR4/MyD88/NF-κB/NLRP3 signaling axis. In ex vivo experiments, COEE inhibited spontaneous and agonist-induced uterine contractions, attenuated CaCl2-induced contractile recovery, and reduced Bay K 8644 evoked Ca2+-mediated contractions. Collectively, our findings suggested that COEE alleviates PD by attenuating uterine inflammation and abnormal calcium-dependent contractions, supporting its potential use as a functional food source for managing PD.

06
CLINICAL STUDY Free radical biology & medicine (2026) PMID: 41831801 ↗
Cornuside alleviates microglia-mediated neuroinflammation to ameliorate chronic neuropathic pain-induced cognitive impairment via the Nrf2/Sirt3 signaling pathway.
Clinical Trial Synthesis 2026 Clinical Study published in Free radical biology & medicine. Key conclusion: In this study, we demonstrated that cornuside effectively alleviated microglial inflammation and improved cognitive impairment induced by chronic neuropathic pain.
View Original PubMed Abstract ↓

Cognitive impairment induced by chronic neuropathic pain (CNP-CI) is a severe complication that markedly compromises patients' quality of life, functional independence, and overall disease burden. However, current pain management strategies demonstrate limited efficacy in preventing or reversing this cognitive decline. Cornuside, an active flavonoid glycoside isolated from the traditional Chinese herb Cornus officinalis, demonstrates potent anti-inflammatory and antioxidative stress properties, however, its therapeutic potential for the treatment of neuropathic pain remains to be elucidated. In this study, we demonstrated that cornuside effectively alleviated microglial inflammation and improved cognitive impairment induced by chronic neuropathic pain. Mechanistically, cornuside ameliorated microglia-mediated neuroinflammation through activation of the Nrf2/Sirt3 signaling pathway and enhancement of mitophagy. Notably, pharmacological inhibition of Sirt3 markedly counteracted the therapeutic effects of cornuside on microglial inflammation and CNP-CI. Our findings provide new insights into the pharmacological mechanisms of cornuside and suggest its potential as a viable therapeutic approach for CNP-CI.

07
CLINICAL STUDY International journal of molecular sciences (2026) PMID: 41828723 ↗
Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment.
Clinical Trial Synthesis 2026 Clinical Study published in International journal of molecular sciences. Key conclusion: In conclusion, these results demonstrate that the MC extract possesses potent neuroprotective and learning- and memory-enhancing effects, highlighting its potential as a therapeutic candidate for managing age-related cognitive decline and MCI.
View Original PubMed Abstract ↓

Mild cognitive impairment (MCI) represents an intermediate stage between normal aging and Alzheimer's disease. This study investigated the neuroprotective effects of a combined extract of Mentha piperita (MP) and Cornus officinalis (CO) (MC) using in vitro and in vivo models. In SK-N-SH cells, pretreatment with MC (50-150 μg/mL) significantly attenuated H2O2-induced cellular injury, as evidenced by a reduction in Annexin V-positive cells and an increase in brain-derived neurotrophic factor (BDNF) mRNA expression. Rosmarinic acid and loganin, the marker compounds of MP and CO, alone or combined at a 6:4 ratio, mitigated H2O2-induced decreases in cell viability and BDNF mRNA. In the in vivo study, male Sprague-Dawley rats were orally administered MC (50, 100, or 200 mg/kg/day) for 28 days, with phosphatidylserine (50 mg/kg/day) serving as a positive control. MC administration significantly improved cognitive performance in rats with scopolamine-induced memory impairment, as demonstrated by increased step-through latency in the passive avoidance test and reduced escape latency in the Morris water maze. Furthermore, in the probe trial, MC-treated rats spent significantly more time in the target quadrant, indicating enhanced spatial memory retention. Mechanistically, MC restored hippocampal acetylcholine levels and reversed the scopolamine-induced decrease in BDNF and its downstream signaling. Specifically, MC upregulated hippocampal BDNF expression and enhanced the phosphorylation of extracellular signal-regulated kinase (ERK), protein kinase B (AKT), and cAMP response element-binding protein (CREB). In conclusion, these results demonstrate that the MC extract possesses potent neuroprotective and learning- and memory-enhancing effects, highlighting its potential as a therapeutic candidate for managing age-related cognitive decline and MCI.

08
CLINICAL STUDY European journal of pharmacology (2026) PMID: 41651331 ↗
Morroniside alleviates neuroinflammation in ischemic injury by mediating microglial pyroptosis via the IL-17/NF-κB/NLRP3 pathway.
Clinical Trial Synthesis 2026 Clinical Study published in European journal of pharmacology. Key conclusion: Morroniside treatment significantly attenuated microglial activation, as evidenced by reduced ionized calcium-binding adapter molecule 1 (IBA-1) expression, and suppressed pyroptosis through downregulation of gasdermin D (GSDMD), NOD-like receptor family pyrin domain containing 3
View Original PubMed Abstract ↓

Ischemic stroke (IS) remains a major cause of global mortality and disability, with neuroinflammation driven by microglial pyroptosis representing a key pathological mechanism. This study examined the neuroprotective efficacy of morroniside-an iridoid glycoside from Cornus officinalis-in experimental model of IS, focusing on its regulation of microglial inflammasome activation, pyroptosis and associated signaling cascades. Using a transient middle cerebral artery occlusion/reperfusion (tMCAO/R) model in Sprague-Dawley rats and an oxygen-glucose deprivation/reperfusion (OGD/R) model in BV2 microglia, morroniside was administered at 270 mg/kg intragastrically in vivo and at concentrations of 1-100 μmol/L in vitro. Protein expression was assessed by Western blotting, cellular markers by immunofluorescence, cytokine levels by enzyme-linked immunosorbent assay (ELISA), and pathway alterations by transcriptomic profiling. Morroniside treatment significantly attenuated microglial activation, as evidenced by reduced ionized calcium-binding adapter molecule 1 (IBA-1) expression, and suppressed pyroptosis through downregulation of gasdermin D (GSDMD), NOD-like receptor family pyrin domain containing 3 (NLRP3), caspase-1, interleukin-1β (IL-1β), and interleukin-18 (IL-18) in both models. Transcriptomic analysis revealed marked enrichment in inflammatory and immune response pathways, with notable suppression of interleukin-17 (IL-17) signaling. Mechanistic analyses showed that morroniside concurrently suppressed IL-17 expression, nuclear factor-κB (NF-κB) phosphorylation, and NLRP3 inflammasome assembly, implicating coordinated inhibition of the IL-17/NF-κB/NLRP3 cascade. Functional in vitro assays confirmed the pathway's essential role: recombinant IL-17 partially reversed, whereas selective IL-17 blockade enhanced, morroniside-mediated suppression of pyroptosis, demonstrating that IL-17 signaling is both necessary and targetable in this cascade. Collectively, these findings identify morroniside as a regulator of IS-associated neuroinflammation that mitigates microglial pyroptosis by interrupting the IL-17/NF-κB/NLRP3 axis, underscoring its potential as a therapeutic candi

09
CLINICAL STUDY Carbohydrate polymers (2026) PMID: 41611434 ↗
Structure characteristics of a pectic polysaccharide from the leaves of Cornus officinalis Sieb. et Zucc. (Shanzhuyu) and its inhibition on hepatocellular carcinoma.
Clinical Trial Synthesis 2026 Clinical Study published in Carbohydrate polymers. Key conclusion: officinalis leaves, as a potential therapeutic agent against HCC by targeting PKM2.
View Original PubMed Abstract ↓

Hepatocellular carcinoma (HCC) represents a highly aggressive malignancy with limited treatment options. While the traditional herb Cornus officinalis Sieb. et Zucc. (C. officinalis, commonly called Asiatic dogwood or "Shanzhuyu" in Chinese) is known for its hepatoprotective properties, the structural features and anti-HCC potential of polysaccharides from its leaves remain largely unexplored. Therefore, we hypothesized that the leaf-derived polysaccharides with uncharacterized structure may exhibit anti-HCC activity. In this study, a homogeneous anti-HCC polysaccharide, designated PCL-2I (Mw = 67.0 kDa), was isolated from C. officinalis leaves, and its structure was characterized by monosaccharide composition, methylation analysis, partial acid hydrolysis, and NMR spectra. PCL-2I is a pectic polysaccharide with a backbone repeating unit: →[6,3)-β-Glcp-(1 → 6)-α-Galp-(1 → 6)-α-Galp-(1]x → [4)-α-GalpA-(1 → 4)-β-GalpA-OMe-(1]y → [4)-α-GalpA-(1 → 2,4)-α-Rhap-(1 → 4)-α-GalpA-(1 → 2)-α-Rhap-(1]z→. Its branched side chains include →6)-α-Galp-(1→, →3)-α-Araf-(1→, →3,5)-α-Araf-(1→, and →2)-α-Rhap-(1→, with substitutions at C-3 of the Glc residue and C-4 of Rha residue, respectively. PCL-2I suppressed HCC growth in vivo and induced apoptosis in vitro by targeting pyruvate kinase M2 (PKM2), thereby attenuating glycolysis and disrupting hypoxia-inducible factor-1α oncogenic signaling. These effects may be attributed to PCL-2I's high content of arabinose and galactose. This study provides a theoretical foundation for utilizing PCL2I, a pectic polysaccharide from C. officinalis leaves, as a potential therapeutic agent against HCC by targeting PKM2.

10
CLINICAL STUDY Phytotherapy research (2026) PMID: 41502346 ↗
Morroniside Modulates Microglia Polarization via the CX3CL1/CX3CR1/PU.1 Axis in ApoE4 Transgenic Mice.
Clinical Trial Synthesis 2026 Clinical Study published in Phytotherapy research. Key conclusion: Our findings indicate that Mor can inhibit neuroinflammation, reduce Aβ accumulation, and improve synaptic damage in ApoE4 mice via the CX3CL1/CX3CR1/PU.1 pathway regulating the phenotype and function of microglia.
View Original PubMed Abstract ↓

Microglia monitor disease stimulation, neuronal apoptosis, and neural repair, and their overactivation-induced inflammation plays a key role in the pathogenesis of Alzheimer's disease (AD). Morroniside (Mor), an iridoid glycoside compound in Cornus officinalis, is one of the effective active components. The effects of Mor on antioxidant stress, antiapoptosis, and nerve repair function have been widely studied, but the mechanism of Mor in AD treatment remains unclear. To study the neuroprotective effects of Mor and elucidate the molecular mechanisms underlying its improvement of AD symptoms, we used ApoE4 transgenic mice and ApoE4-transfected BV2 cells as models of AD, focusing on microglia phenotype, function, and neuroinflammation. The 10-month-old mice were randomly divided into the ApoE3 control group (ApoE3 + Veh), the ApoE4 model group (ApoE4 + Veh), and the ApoE4 + Mor 10, 20, and 40 mg/kg groups as in vivo models. The in vitro BV2-ApoE model was constructed via lentiviral transfection. The effects of Mor on cognitive function of AD models were assessed through behavioral tests, western blot, immunofluorescence staining, and ELISA to measure changes of related pathological and inflammatory factors. Mor improved the cognitive function of ApoE4 transgenic mice by reducing Aβ plaques in the brain, improving the structural lesions of hippocampal neurons, and increasing synaptic plasticity in the brain of AD mice. In addition, Mor promoted the transformation of microglia from the M1 to the M2 phenotype, inhibited the activation of the CX3CR1/PU.1 signaling axis, and alleviated the dysfunction of microglia both in vitro and in vivo. CX3CR1 siRNA and PU.1 siRNA were used further to verify the regulatory effect of Mor on microglia phenotype. Our findings indicate that Mor can inhibit neuroinflammation, reduce Aβ accumulation, and improve synaptic damage in ApoE4 mice via the CX3CL1/CX3CR1/PU.1 pathway regulating the phenotype and function of microglia. This study provides a new therapeutic candidate for the prevention and treatment of AD. © 2026 John Wiley & Sons, Ltd.

RELATED MONOGRAPHS

Related Monographs in This Category